Merck CEO sees Keytruda in pole position in cancer race

Chairman and CEO of Merck & Co., Kenneth Frazier, takes part in a panel discussion during the Clinton Global Initiative's annual meeting in New YorkBy Ben Hirschler DAVOS, Switzerland (Reuters) – Merck & Co&;s Keytruda cancer drug, which last week won a speedy review from U.S. regulators for use with chemotherapy in lung cancer, is in an increasingly strong position in a fiercely competitive market, the company&039;s CEO said on Thursday. Chief Executive Ken Frazier said that Keytruda would also be cheaper than some rival approaches — an increasingly important consideration in an era of heightened controversy about high drug prices. The U.S. Food and Drug Administration (FDA) is due to decide by May 10 whether to approve a combination of the immune system-boosting drug with chemotherapy as an initial therapy for advanced lung cancer, the largest cancer market.

Go to Source

Sweating in sauna might help keep brain healthy: Finnish study

Man leaves sauna during Belarusian winter swimming championship in MinskRegular visits to the sauna can help lower the risk of developing dementia and Alzheimer&;s disease as well as dying of heart ailments, a Finnish study suggests. Researchers at the University of Eastern Finland found a link between sauna visits and memory diseases after following more than 2,300 middle-aged Finnish men for more than 20 years. In the study, men who went to the sauna four to seven times a week were found 66 percent less likely to be diagnosed with dementia, and 65 percent less likely with Alzheimer&039;s disease, than those taking a sauna once a week.

Go to Source

1 3 4 5 6 7 11